Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | ESR1 | P03372 | 2/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 2/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9854456 | 0.95 | CYP3A4 (0.52) | CYP3A4TDP1ESR1ESR2TSHR | |
| SCHEMBL29518446 | 0.95 | CYP3A4 (0.52) | CYP3A4TDP1ESR1ESR2TSHR | |
| SCHEMBL29672644 | 0.93 | CYP3A4 (0.50) | CYP3A4TDP1ESR1ESR2TSHR | |
| SCHEMBL31158056 | 0.93 | CYP3A4 (0.50) | CYP3A4TDP1ESR1ESR2TSHR | |
| SCHEMBL29996019 | 0.93 | CYP3A4 (0.50) | CYP3A4TDP1ESR1ESR2TSHR | |
| SCHEMBL31258429 | 0.91 | CYP3A4 (0.48) | CYP3A4TDP1ESR1ESR2TSHR | |
| SCHEMBL10596637 | 0.91 | CYP3A4 (0.48) | CYP3A4TDP1ESR1ESR2TSHR | |
| SCHEMBL30046611 | 0.91 | CYP3A4 (0.52) | CYP3A4TDP1ESR1ESR2TSHR | |
| SCHEMBL2454266 | 0.91 | CYP3A4 (0.52) | CYP3A4TDP1ESR1ESR2TSHR | |
| SCHEMBL29802201 | 0.83 | CYP3A4 (0.44) | CYP3A4TDP1ESR1ESR2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197908-A1 | Pyridazine Derivatives with MCH Antagonistic Activity and Medicaments Comprising These Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197908-A1 | Pyridazine Derivatives with MCH Antagonistic Activity and Medicaments Comprising These Compounds | MCHR1, MCHR2, MC5R | CYP3A4 2304/4885TDP1 4031/4885ESR1 1819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.